Genelux Corp.

Genelux Corp. is a biotechnology company focused on the development and commercialization of innovative oncolytic immunotherapies. The primary function of Genelux is to harness the potential of their proprietary oncolytic virus platform to treat various types of cancer. The company centers its research and development efforts on creating viral products that can selectively replicate within cancer cells to destroy them while sparing healthy tissue. This groundbreaking approach aims to enhance the body's immune response against tumors, offering new treatment possibilities for patients with hard-to-treat cancers. Genelux’s contributions to the biotechnology and healthcare sectors are significant, as they provide promising alternatives to traditional cancer therapies such as chemotherapy and radiation. By tapping into genetic engineering and virology, Genelux plays a pivotal role in the evolving landscape of precision medicine, offering a targeted approach that could improve treatment efficacy and reduce side effects. As a key player in the biotech market, Genelux continues to innovate, collaborating with research institutions and healthcare providers to advance its pipeline products through clinical trials and towards regulatory approval.